Megan Rogers
Endocrinology, Diabetes & Metabolism · San Diego, CANPI 1982993374
Payments from drug & device makers
Across 137 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$412
- Novo Nordisk$347
- Dexcom, Inc.$200
- Mannkind Corporation$164
- Tandem Diabetes Care, Inc.$141
- Insulet Corporation$112
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,34698%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $412 |
| Novo Nordisk | 16 | $347 |
| Dexcom, Inc. | 8 | $200 |
| Mannkind Corporation | 8 | $164 |
| Tandem Diabetes Care, Inc. | 7 | $141 |
| Insulet Corporation | 3 | $112 |
| Boehringer Ingelheim | 6 | $101 |
| Amgen(2 entities) | 5 | $100 |
| Astellas Pharma US Inc | 3 | $73 |
| Abbott | 4 | $71 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| GSK | 2 | $64 |
| Johnson & Johnson | 3 | $58 |
| Medtronic(2 entities) | 3 | $54 |
| Hologic Sales And Service, LLC | 2 | $53 |
| Bayer | 2 | $49 |
| Corcept Therapeutics | 3 | $48 |
| Viiv Healthcare Company | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| AstraZeneca | 2 | $33 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| AbbVie | 1 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| Zimmer Biomet | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Cequr Corporation | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$125
How this compares
$2,404 in reported general payments places this provider in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 238 | $243,413 |
| TrulicityDulaglutide | 173 | $226,390 |
| JardianceEmpagliflozin | 247 | $193,121 |
| MounjaroTirzepatide | 94 | $119,512 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $36,560 |
| TradjentaLinagliptin | 38 | $28,519 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $18,388 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $18,338 |
| ProliaDenosumab | 11 | $17,712 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $16,742 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $13,749 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $11,541 |
| JanuviaSitagliptin Phosphate | 19 | $11,091 |
| FarxigaDapagliflozin Propanediol | 12 | $10,395 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 100 | $9,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $412 | $346,642278 claims |
| Novo NordiskOzempic | $347 | $243,413238 claims |
| Boehringer IngelheimJardiance, Tradjenta | $101 | $221,640285 claims |
| AmgenProlia | $100 | $17,71211 claims |
| MerckJanuvia | $11 | $11,09119 claims |
| AstraZenecaFarxiga | $33 | $10,39512 claims |
| AbbVieSynthroid | $25 | $2,43935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in San Diego
- Jerrold OlefskySan Diego$26.5M
- Juan FriasSan Diego$14.1M
- Ken FujiokaSan Diego$750K
- Raymond PlodkowskiSan Diego$546K
- Jeremy PettusSan Diego$544K
- Schafer BoederSan Diego$357K
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Paul NorwoodFresno$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.